OTCMKTS:SLNCF Silence Therapeutics (SLNCF) Stock Price, News & Analysis $6.50 0.00 (0.00%) (As of 07/1/2024 ET) Add Compare Share Share Today's Range$6.50▼$6.5050-Day Range$6.50▼$8.0052-Week Range$0.60▼$10.90VolumeN/AAverage Volume1,128 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Silence Therapeutics alerts: Email Address Ad Crypto 101 MediaThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details… About Silence Therapeutics Stock (OTCMKTS:SLNCF)Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.Read More SLNCF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLNCF Stock News HeadlinesMay 29, 2024 | yahoo.comAfter the Silence Streaming: Watch & Stream Online via Amazon Prime VideoMay 29, 2024 | msn.comAnupriya Goenka on Break The Silence making it to Cannes 2024: There is a certain credibilityJuly 2, 2024 | Paradigm Press (Ad)Biden’s inner circle turns against him?On August 19, the Democratic party will take the stage in Chicago and officially nominate their presidential candidate for the 2024 election. But it’s possible their nominee will NOT be Joe Biden.May 29, 2024 | yahoo.comDisturbed’s “The Sound of Silence” Video Passes One Billion Views on YouTubeMay 29, 2024 | msn.comSilence the Violence: Advocates calling for end to gun violenceMay 29, 2024 | msn.comLate Lee Sun-kyun's 'Project Silence' to premiere in JulyMay 16, 2024 | finanznachrichten.deSilence Therapeutics plc: Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline ProgressMay 7, 2024 | msn.comSilence Therapeutics files to sell 5.71M American Depositary Shares for holdersJuly 2, 2024 | Paradigm Press (Ad)Biden’s inner circle turns against him?On August 19, the Democratic party will take the stage in Chicago and officially nominate their presidential candidate for the 2024 election. But it’s possible their nominee will NOT be Joe Biden.May 5, 2024 | forbes.comFor Mental Health Awareness Month, Let’s Vow To Silence The ShameMay 3, 2024 | msn.comSilence 2 actor Prachi Desai: I don’t take the pressure if I don't have a release in a yearMay 3, 2024 | msn.comHow to complete the Radio Silence quest in Gray Zone WarfareApril 28, 2024 | msn.comPrachi Desai returns in 'Silence 2': higher stakes and a bolder inspector BhatiaApril 28, 2024 | msn.comGet published - enter the Songs of Silence art contestApril 28, 2024 | msn.comIn Sheryl Sandberg's 'Screams Before Silence' Doc, Survivors of Oct. 7 Sexual Violence Speak: 'Mom, They're Going to Rape Me Now'April 26, 2024 | msn.com'Silence 2' director Aban Bharucha Deohans shares experience working with Manoj Bajpayee, Prachi DesaiApril 26, 2024 | msn.comSilence 2 actor Manoj Bajpayee: Nobody is a superstar on OTT; I'm happy to be relevant and workingApril 26, 2024 | usnews.comBlinken Says Gaza Protests a Hallmark of Democracy, Decries 'Silence' on HamasApril 23, 2024 | msn.comRadio Silence teases bombshell Abigail-Ready or Not connectionApril 16, 2024 | msn.comMovie review: Radio Silence brings maximalist style to vampire flick 'Abigail'April 16, 2024 | msn.comChinese Pop Idol Silence Wang’s Career Under Fire Amidst Sexual Harassment ClaimsApril 9, 2024 | msn.comColorado Springs Cycling Club honors fallen cyclists with “Ride Of Silence” eventApril 9, 2024 | msn.comQuiet on Set: Breaking the Silence Doesn't Let Dan Schneider Have the Last WordApril 4, 2024 | usnews.comDescendants of Enslaved, Enslavers 'Break Silence' Around France's PastApril 3, 2024 | msn.comManoj Bajpayee, Prachi Desai on mission to solve shootout in 'Silence 2'March 31, 2024 | msn.comScream: Radio Silence Discusses Leaving the FranchiseMarch 29, 2024 | msn.comReady or Not 2 gets update with disappointing Radio Silence twistSee More Headlines Receive SLNCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:SLNCF CUSIPN/A CIK1479615 Webwww.silence-therapeutics.com Phone442034576900FaxN/AEmployees109Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Craig A. Tooman M.B.A. (Age 59)President, CEO & Executive Director Comp: $1.49MMs. Rhonda L. Hellums (Age 51)CFO & Secretary Comp: $907.23kDr. Steven J. Romano M.D. (Age 65)Head of Research & Development Comp: $662.65kDr. Marie Wikstrom Lindholm Ph.D.Chief Scientific OfficerMs. Gem Gokmen HopkinsHead of IR & Corporate CommunicationsDr. Barbara A. Ruskin J.D. (Age 63)Ph.D., Senior VP and Chief Intellectual Property & Innovation Officer Dr. Eric Floyd M.B.A. (Age 61)M.S., Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance Mr. J.P. GabrielChief Technical Operations OfficerMr. Curtis Rambaran M.D.Chief Medical OfficerMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors SLNCF Stock Analysis - Frequently Asked Questions How have SLNCF shares performed in 2024? Silence Therapeutics' stock was trading at $1.50 at the beginning of 2024. Since then, SLNCF shares have increased by 333.3% and is now trading at $6.50. View the best growth stocks for 2024 here. Are investors shorting Silence Therapeutics? Silence Therapeutics saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 2,600 shares, an increase of 333.3% from the May 31st total of 600 shares. Based on an average daily volume of 700 shares, the days-to-cover ratio is currently 3.7 days. View Silence Therapeutics' Short Interest. How do I buy shares of Silence Therapeutics? Shares of SLNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SLNCF) was last updated on 7/2/2024 by MarketBeat.com Staff From Our PartnersWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBiden Debate DisasterBiden was a disaster in the debate. Trump looked 100% more presidential. Biden’s campaign is DONE… But t...Banyan Hill Publishing | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredCatalyst Could Trigger 10,000% Crypto GainsFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
